Skip to contentA
Abbott Laboratories
A
ABTAbbott Laboratories Source filing unavailable
Q4 2013 · —
Revenue$5.07B$5.07B−9.9% vs Q4 2012 Net Income$589.00M$589.00M−44.1% vs Q4 2012 EPS Diluted$0.37$0.37−43.9% vs Q4 2012 Gross Profit$2,551,000,000−10.1% Operating Incomederived$418,000,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Abbott Laboratories · CIK 1800 · Engraved from SEC EDGAR
Operating Cash Flowderived$1,625,000,000+8.1% Free Cash Flowderived$1,322,000,000+18.4% Margins · derivedGross margin50.3%−0.1 pt vs Q4 2012
Operating margin8.2%+8.7 pt vs Q4 2012
Net margin11.6%−7.1 pt vs Q4 2012